DEVELOPMENT AND MANUFACTURE OF MICROBIAL-DERIVED BIOPHARMACEUTICALS
Richter-Helm is a leading and steadily growing biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with two cGMP-compliant manufacturing facilities in Germany.
We specialize in products derived from bacteria and yeasts. Over the past 30 years we gained substantial experience in the development and manufacture of different product types that include recombinant proteins and peptides, plasmid DNA, and bacterial vaccines.
We move our clients projects forward: flexible, transparent, fast
Our Expertise
- Strong track record in microbial production of biopharmaceuticals
- Specialized in products derived from bacteria and yeasts
- Customer base includes established large pharmaceutical companies and start-ups worldwide
- Production of commercial and both early- and late-stage products
- Project Management
- Strain-/ Process- and Analytical Development
- Bioassay development
Our Microbial Capabilities
- Headquarters in Hamburg and two GMP-compliant manufacturing facilities in Hannover and Bovenau, Germany
- GMP facilities approved by major regulatory bodies including EMA, FDA, PMDA, ANVISA, and MFDS
- Flexible production capabilities with fermenter volumes from 10 to 1500 litres and suitable DSP capacities
- Batch and fed-batch manufacture
- Methanol feeding for Pichia expression
- Continuous expansion of process development, quality control and production capacities
- Extension of capacities planned
Our company in numbers
How Richter-Helm Overcomes the Challenges of the Covid-19 Pandemic
Latest News
Covid-19 vaccination at Richter-Helm
Richter-Helm is very pleased to be able to offer its employees to get vaccinated against Covid-19 by the company doctors.
German CDMO Richter-Helm Triples cGMP Production Capacity to Accommodate Global Market Demand
Richter-Helm announced today the start of construction for an expansion project at its cGMP manufacturing facility in Bovenau, Germany. The new multi-product biological manufacturing facility is expected to begin full-scale operations and manufacturing by the end of 2023.
Hoffnungsträger aus Hamburg
Seit mehr als einem Jahr hält Corona die Welt in Atem. Nun herrscht Erleichterung darüber, dass dank der Entwicklung von Impfstoffen mit der Immunisierung der Bevölkerung begonnen werden konnte. Auch Richter-Helm ist an der Produktion eines Impfstoffes gegen COVID-19 beteiligt.
INOVIO Expands Manufacturing of COVID-19 DNA Vaccine INO-4800 With New Funding from CEPI
INOVIO (NASDAQ:INO) today announced it has entered into an agreement to expand its manufacturing partnership with the German contract manufacturer Richter-Helm BioLogics GmbH & Co. KG, to support large-scale manufacturing of INOVIO’s investigational DNA vaccine INO-4800…
